Hims & Hers CEO Pushes Back Hard on FTC Lawsuit
Andrew Dudum tells CNBC the FTC fundamentally misunderstands Hims & Hers' business model amid a lawsuit over compounded GLP-1 drugs.
The FTC came after Hims & Hers, and CEO Andrew Dudum isn't backing down. Dudum went straight to CNBC to fire back at the federal agency's lawsuit, arguing regulators simply don't understand how his company actually operates. That's a bold stance — and one that matters if you're holding HIMS stock or watching the compounded drug space.
At the center of the fight are compounded GLP-1 drugs — essentially customized versions of blockbuster weight-loss and diabetes medications. Hims & Hers built a real business selling these alternatives, and the FTC clearly has a problem with how that's being done. Dudum's counter is that the agency's framework doesn't map onto his company's model. Whether the courts agree is the multi-billion-dollar question.
Read more Costco Teams Up With SCAN Group to Offer Medicare Advantage →
Dudum also brought AI into the conversation during his CNBC appearance, signaling that Hims & Hers sees technology as a core part of its future — not just a buzzword. That's worth watching. A telehealth platform leaning into AI while simultaneously fighting off a federal lawsuit is either visionary or overextended, depending on how the legal battle plays out.
For traders, this is a high-risk, high-drama setup. Regulatory outcomes can crater or catapult a stock like HIMS overnight. The FTC's willingness to sue tells you the agency is serious. Dudum's willingness to go on TV and argue back tells you he's not settling quietly. Buckle up — this one isn't over fast.
Continue reading at US Top News and Analysis
